RYE, N.Y., April 25, 2011 /PRNewswire/ -- Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced today that its compound CM-182 demonstrated positive results for schizophrenia in the transgenic chakragati (ckr) model of psychosis. The mouse model screening was performed by the Contract Research Organization, Cerca Insights.
The chakragati mouse, considered a model for screening antipsychotic compounds, exhibits abnormal circling behavior and hyperactivity in response to environmental stress cues and also anti-social behaviors. When administered Curemark's CM-182, the mice demonstrated dose-related decreases in the hyperactive behaviors. In the landmark paper published in Neuroscience in 2010 (Dawe, et al.), it was demonstrated that the ckr mouse was predictive of antipsychotic efficacy based on decreased hyperactivity.
"Our findings in the ckr mouse model are illustrative of improvement in the positive class of schizophrenic symptoms," says Dr. Matthew Heil, Executive Vice President of Drug Development and Research. "Based on these findings, we are further investigating CM-182's potential to affect the negative class symptoms associated with schizophrenia."
"We are pleased that we received encouraging results," states Dr. Joan Fallon, CEO of Curemark. "Our results demonstrate that our novel compound indeed shows promise for schizophrenia and/or hyperactivity. We intend to develop CM-182 and to initiate an Investigative New Drug application in the near future."
Curemark recently announced that the company has completed enrollment of Phase III clinical trials for CM-AT, its autism treatment.
About CUREMARK, LLC
Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com.
Safe Harbor Statement
This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of the Curemark products CM-AT, CM-4612 and CM-182 their potential advantages, their potential for use in treating diseases or disorders, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning the Curemark products CM-AT, CM-4612 and CM-182. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of the Curemark products CM-AT, CM-4612 and CM-182, our ability to finance our development of CM-AT, CM-4612 and CM-182 regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.
SOURCE Curemark, LLC